Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP1 | P29466 | 1/20 | 0.47 |
| ▸ | CASP7 | P55210 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | PGR | P06401 | 2/20 | 0.46 |
| ▸ | GRM5 | P41594 | 2/20 | 0.44 |
| ▸ | HSD17B1 | P14061 | 3/20 | 0.42 |
| ▸ | MAOB | P27338 | 5/20 | 0.38 |
| ▸ | DHODH | Q02127 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.38 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.38 |
| ▸ | MAOA | P21397 | 1/20 | 0.38 |
| ▸ | PRKCI | P41743 | 1/20 | 0.38 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.36 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30382651 | 0.80 | CASP1 (0.55) | CASP1CASP7HSD17B10PGRGRM5 | |
| SCHEMBL85043 | 0.80 | CASP1 (0.55) | CASP1CASP7HSD17B10PGRGRM5 | |
| SCHEMBL1726500 | 0.80 | PARP10 (0.55) | GRM5 | |
| SCHEMBL28363380 | 0.77 | CASP1 (0.52) | CASP1CASP7HSD17B10PGRGRM5 | |
| SCHEMBL13186636 | 0.75 | PARP10 (0.36) | GRM5DHODHCYP11B1CYP11B2 | |
| SCHEMBL14163813 | 0.75 | NPC1 (0.54) | CASP1CASP7HSD17B10PGRGRM5 | |
| SCHEMBL2388879 | 0.73 | CASP1 (0.55) | CASP1CASP7HSD17B10GRM5HSD17B1 | |
| SCHEMBL10627415 | 0.72 | MAOA (0.56) | CASP1CASP7HSD17B10PGRGRM5 | |
| SCHEMBL1031985 | 0.72 | GRM5 (0.62) | CASP1CASP7HSD17B10PGRGRM5 | |
| SCHEMBL29741348 | 0.72 | GRM5 (0.62) | CASP1CASP7HSD17B10PGRGRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8487116-B2 | Fused compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor | ABBVIE INC. (US) | 2013-07-16 | — | — | US | disclosed |
| CN-102617464-A | fused compounds that inhibit vanilloid receptor subtype 1 (vr1) receptor | ABBOTT LAB | 2012-08-01 | — | — | CN | disclosed |
| US-20120190845-A1 | FUSED COMPOUNDS THAT INHIBIT VANILLOID RECEPTOR SUBTYPE 1 (VR1) RECEPTOR | ABBVIE INC. | 2012-07-26 | — | — | US | disclosed |
| US-8071762-B2 | Fused compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor | ABBOTT LABORATORIES (US) | 2011-12-06 | — | — | US | disclosed |
| EP-2017265-B1 | Fused compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor | ABBOTT LAB (US) | 2011-05-25 | — | — | EP | disclosed |
| CN-101445501-A | Fused compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor | ABBOTT LAB (US) | 2009-06-03 | — | — | CN | disclosed |
| EP-2017265-A1 | Fused compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor | Abbott Laboratories (US) | 2009-01-21 | — | — | EP | disclosed |
| US-20080287676-A1 | FUSED COMPOUNDS THAT INHIBIT VANILLOID RECEPTOR SUBTYPE 1 (VR1) RECEPTOR | ABBOTT LABORATORIES (US) | 2008-11-20 | — | — | US | disclosed |
| EP-1658269-B1 | FUSED COMPOUNDS THAT INHIBIT VANILLOID RECEPTOR SUBTYPE 1 (VR1) RECEPTOR | ABBOTT LAB (US) | 2008-10-22 | — | — | EP | disclosed |
| US-7375126-B2 | Fused compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor | ABBOTT LABORATORIES (US) | 2008-05-20 | — | — | US | disclosed |
| CN-1835924-A | Fused compounds that inhibit vanilloid receptor subtype 1(vr1) receptor | ABBOTT LAB (US) | 2006-09-20 | — | — | CN | disclosed |
| EP-1658269-A1 | FUSED COMPOUNDS THAT INHIBIT VANILLOID RECEPTOR SUBTYPE 1 (VR1) RECEPTOR | Abbott Laboratories (US) | 2006-05-24 | — | — | EP | disclosed |
| US-20050043351-A1 | Fused compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor | ABBVIE INC. | 2005-02-24 | — | — | US | disclosed |
| WO-2004111009-A1 | FUSED COMPOUNDS THAT INHIBIT VANILLOID RECEPTOR SUBTYPE 1 (VR1) RECEPTOR | ABBOTT LABORATORIES (US) | 2004-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080287676-A1 | FUSED COMPOUNDS THAT INHIBIT VANILLOID RECEPTOR SUBTYPE 1 (VR1) RECEPTOR | ARRB1, TRPV1, TRPV5 | CASP1 725/4885CASP7 2750/4885HSD17B10 2590/4885 |
| US-20050043351-A1 | Fused compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor | ARRB1, TRPV1, TRPV5 | CASP1 678/4885CASP7 2692/4885HSD17B10 2652/4885 |
| US-20120190845-A1 | FUSED COMPOUNDS THAT INHIBIT VANILLOID RECEPTOR SUBTYPE 1 (VR1) RECEPTOR | ARRB1, TRPV1, TRPV5 | CASP1 725/4885CASP7 2750/4885HSD17B10 2590/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.